ISSN 1758-4272 10.2217/IJR.13.70 © 2014 Future Medicine Ltd Int. J. Clin. Rheumatol. (2014) 9(1), 1–3 “A high index of suspicion in order to make an early diagnosis, as well as aggressive therapy, are vital for the survival of catastrophic antiphospholipid syndrome patients. However, in a ‘real-world’ setting, even if catastrophic antiphospholipid syndrome is considered in the differential diag...

We present a 12-year-old girl with systemic lupus erythematosus and associated antiphospholipid syndrome who developed an unusual manifestation of purpura fulminans in an accelerated fashion. The patient improved after prompt treatment with anticoagulants, aggressive immunosuppressive drugs and plasmapheresis. This is the first pediatric case of purpura fulminans due to secondary antiphospholip...

In 1991, the Haemostasis and Thrombosis Task Force of the British Society for Haematology published guidelines on testing for the lupus anticoagulant (LA) (Machin et al, 1991). Since then there have been major developments in our understanding of the nature of `antiphospholipid antibodies' (aPLs) and improvements in our knowledge of the clinical course of the antiphospholipid syndrome. These re...

Antiphospholipid syndrome (APS) has been recognized as one of the most commontypes of thrombophilia (1). Its main clinical features are arterial/venous thrombosis and pregnancy loss associated with placenta thrombosis. However, other heterogeneous clinical manifestations may be associated with APS, such as thrombocytopenia, haemolytic anemia, neurological impairment and pulmonary hypertension (...

Cutaneous involvement in primary and secondary antiphospholipid syndrome often is a therapeutical dilemma. Here we describe a case of widespread cutaneous necrosis due to thrombosis of the microvasculature, and cutaneous vasculitis in secondary antiphospholipid syndrome in a patient with systemic lupus erythematosus. Autologous skin transplantation was able to cover the skin defects but was onl...

The aim of the research was to show our diagnostic and therapeutic experience with antiphospholipid syndrome (APS) in pregnant women. 36 pregnant women suspect on APS were included in the study: 32 with primary antiphospholipd syndrome (PAPS) and 4 with secondary antiphospholipid syndrome (SAPS). All pregnant women received low-molecular-weight-heparin (LMWH) and low dose aspirin (LDA) therapy....

Purpose We present a patient with systemic lupus erythematosus with significant vaso-occlusive retinal findings mimicking antiphospholipid antibody syndrome, who developed Kikuchi-Fujimoto disease. Observations Our patient was initially diagnosed with systemic lupus erythematosus with antiphospholipid antibody syndrome given consistent serologic markers and profound retinal vascular ischemia....

Recurrent fetal losses indicate screening for antiphospholipid antibodies, especially after the third consecutive fetal loss, or when they occur after 12 weeks gestation or when the mother presents with thrombosis or other ailments of antiphospholipid syndrome. Fetal loss may be caused by thromboses of placental vasculature. There is no agreement concerning the mechanism of thromboses: protein ...

Antiphospholipid syndrome (APS) is recognized as one of the main determinants of hypercoagulable conditions. The literature reports the incidence of this syndrome in a third of patients who underwent surgery for peripheral revascularization. Antiphospholipid antibodies are divided into two categories in relation to specific diagnostic tests. The first group is called lupus anticoagulant and con...

In this study we investigated skin bacterial colonization, allergen-specific IgE and antiphospholipid/antinuclear antibodies in 72 children with atopic eczema/dermatitis syndrome (age 2-17 years). Bacteria were found on the skin in 41 cases and serological allergen-specific IgE positivity in 37. The different forms of antibodies appeared in the ratio 21/72 (33 antibodies in 21 children). The oc...